Immunome Inc. (IMNM)
Market Open
11 Sep, 16:01
NASDAQ (CM) NASDAQ (CM) Primary $
24. 94
-0.03
-0.1201%
$
2.56B Market Cap
- P/E Ratio
- Div Yield
16,453 Volume
-2 Eps
$ 24.97
Previous Close 
Want to track IMNM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Immunome: AL102 And Other Established Protein Targets Could Drive Value
Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-drug conjugate being developed to target ROR1 expressing solid tumors; IND filing to begin a phase 1 study for this program, expected Q1 of 2025.
Seekingalpha | 2 years ago
